ClinicalTrials.Veeva

Menu
Research Associates of South Florida | Miami, FL logo

Research Associates of South Florida | Miami, FL

Research site

Site insights

Top conditions

Top treatments

Mirikizumab
Etrasimod
Ozanimod
ABX464
Lutikizumab
EDP-305
Mesalamine
AVP-786
Risankizumab
SAR442970

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

13 of 35 total trials

A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab (Switch-Up)

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. Therapies spread over the skin may not...

Enrolling
Atopic Dermatitis
Drug: Upadacitinib 30mg Dose
Drug: Upadacitinib 15mg Dose

Ulcerative colitis (UC) is a type of inflammatory bowel disease that causes inflammation and bleeding from the lining of the rectum and colon (large...

Active, not recruiting
Ulcerative Colitis
Drug: Adalimumab
Drug: Lutikizumab

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most often affecting the...

Active, not recruiting
Crohn's Disease
Drug: Placebo for risankizumab
Drug: Risankizumab SC

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluat...

Active, not recruiting
Atopic Dermatitis
Drug: Placebo
Drug: Lutikizumab

This study is designed to evaluate the long-term efficacy and safety of mirikizumab in participants with moderately to severely active ulcerative col...

Active, not recruiting
Ulcerative Colitis
Drug: Mirikizumab

This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess t...

Enrolling
Ulcerative Colitis
Drug: SAR442970
Drug: Placebo

This is a multicenter, randomized, placebo-controlled study to evaluate the long-term efficacy and safety of ABX464 50mg and 25mg administered once d...

Active, not recruiting
Ulcerative Colitis
Drug: ABX464
Drug: Placebo

The purpose of this open-label extension (OLE) study is to evaluate the safety and efficacy of etrasimod in participants with moderately to severely...

Active, not recruiting
Ulcerative Colitis
Drug: Etrasimod

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase.The objective is to evaluate...

Enrolling
Moderately to Severely Active Crohn Disease
Drug: Obefazimod
Other: Placebo
Locations recently updated

This study is open to adults who are at least 18 years old and have:* A confirmed liver disease called non-alcoholic steatohepatitis (NASH) or* A con...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis
Combination Product: Survodutide
Combination Product: Placebo matching survodutide
Locations recently updated

This study is open to adults who are at least 18 years old living with obesity and have:* a confirmed liver disease called non-alcoholic steatohepati...

Enrolling
Metabolic Dysfunction Associated Steatohepatitis (MASH)
Liver Fibrosis
Combination Product: Placebo
Combination Product: Survodutide

To determine the safety and efficacy of GIE Medical's ProTractX3™ TTS DCB for the treatment of recurrent benign bowel strictures.

Enrolling
Bowel; Stricture
Other: Control
Combination Product: GIE Medical ProTractX3 TTS DCB

To evaluate the safety and efficacy of the ProTractX3™ DCB for the treatment of benign esophageal strictures.

Enrolling
Esophageal Stricture
Other: Control
Combination Product: GIE Medical ProTractX3 TTS DCB

Trial sponsors

AbbVie logo
Lilly logo
Pfizer logo
A
Celgene logo
Boehringer Ingelheim logo
Enanta Pharmaceuticals logo
Exact Sciences Corporation logo
Ferring logo
G

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems